Asymptomatic cytomegalovirus (CMV) infection is associated with graft dysfunction and failure. However, no study assessed CMV viral load in terms of the risk for graft failure.
Methods
In a prospective cohort of kidney transplant recipients, we assessed the impact of CMV DNAemia on the overall graft survival and the incidence of moderate-to-severe interstitial fibrosis and tubular atrophy (IF/TA) in protocol biopsy at 36 months. CMV DNAemia was stratified by viral load in whole blood.
Results
A total of 180 patients transplanted from October 2003 through January 2011 were included and followed for 4 years; 87 (48%) patients received 3-month prophylaxis with valacyclovir and 45 (25%) with valganciclovir; 48 (27%) were managed by pre-emptive therapy. Within 12 months of transplantation, CMV DNAemia developed in 102 (57%) patients with 36 (20%) having a viral load of ≥2,000 copies/ml. Multivariate Cox analysis identified CMV DNAemia as an independent risk factor for graft loss (hazard ratio 3.42; P=0.020); however, after stratification by viral load, only CMV DNAemia ≥2,000 copies/ml (hazard ratio 7.62; P<0.001) remained significant. Both early-onset (<3 months; P=0.048) and late-onset (>3 months; P<0.001) CMV DNAemia ≥2,000 copies/ml were risk factors for graft loss. The incidence of moderate-to-severe IF/TA was not significantly influenced by CMV DNAemia.
Conclusions
Kidney transplant recipients having CMV DNAemia with a higher viral load irrespective of the time to onset are at increased risk for graft loss.
References
1.
KottonC.N., KumarD., CaliendoA.M.Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation.Transplantation2013; 96: 333–360.
2.
SagedalS., HartmannA., NordalK.P.Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival.Kidney Int2004; 66: 329–337.
ManuelO., KralidisG., MuellerN.J.Impact of antiviral preventive strategies on the incidence and outcomes of cytomegalovirus disease in solid organ transplant recipients.Am J Transplant2013; 13: 2402–2410.
5.
ReischigT., HribovaP., JindraP.Long-term outcomes of pre-emptive valganciclovir compared with valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation.J Am Soc Nephrol2012; 23: 1588–1597.
6.
SternM., HirschH., CusiniA.Cytomegalovirus serology and replication remain associated with solid organ graft rejection and graft loss in the era of prophylactic treatment.Transplantation2014; 98: 1013–1018.
7.
Martin-GandulC., MuellerN.J., PascualM., ManuelO.The impact of infection on chronic allograft dysfunction and allograft survival after solid organ transplantation.Am J Transplant2015; 15: 3024–3040.
8.
ReischigT.Cytomegalovirus-associated renal allograft rejection: new challenges for antiviral preventive strategies.Expert Rev Anti Infect Ther2010; 8: 903–910.
9.
ReischigT., JindraP., SvecovaM., KormundaS., OpatrnyK.Jr., TreskaV.The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection.J Clin Virol2006; 36: 146–151.
10.
ReischigT., JindraP., HesO., BoudaM., KormundaS., TreskaV.Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis.Transplantation2009; 87: 436–444.
11.
SmithJ.M., CoreyL., BittnerR.Subclinical viremia increases risk for chronic allograft injury in pediatric renal transplantation.J Am Soc Nephrol2010; 21: 1579–1586.
12.
CourivaudC., BamoulidJ., ChalopinJ.M.Cytomegalovirus exposure and cardiovascular disease in kidney transplant recipients.J Infect Dis2013; 207: 1569–1575.
13.
ReischigT., JindraP., HesO., SvecovaM., KlabochJ., TreskaV.Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation.Am J Transplant2008; 8: 69–77.
14.
KhouryJ.A., StorchG.A., BohlD.L.Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients.Am J Transplant2006; 6: 2134–2143.
15.
KliemV., FrickeL., WollbrinkT., BurgM., RadermacherJ., RohdeF.Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial.Am J Transplant2008; 8: 975–983.
16.
FlorescuD.F., QiuF., SchmidtC.M., KalilA.C.A direct and indirect comparison meta-analysis on the efficacy of cytomegalovirus preventive strategies in solid organ transplant.Clin Infect Dis2014; 58: 785–803.
17.
HumarA., LebranchuY., VincentiF.The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients.Am J Transplant2010; 10: 1228–1237.
18.
ReischigT., KacerM., JindraP., HesO., LysakD., BoudaM.Randomized trial of valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation.Clin J Am Soc Nephrol2015; 10: 294–304.
SolezK., ColvinR.B., RacusenL.C.Banff ‘05 meeting report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy (‘CAN’).Am J Transplant2007; 7: 518–526.
21.
HaasM., SisB., RacusenL.C.Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions.Am J Transplant2014; 14: 272–283.
22.
ReischigT., NemcovaJ., VanecekT.Intragraft cytomegalovirus infection: a randomized trial of valacyclovir prophylaxis versus pre-emptive therapy in renal transplant recipients.Antivir Ther2010; 15: 23–30.
23.
DzabicM., RahbarA., YaiwK.C.Intragraft cytomegalovirus protein expression is associated with reduced renal allograft survival.Clin Infect Dis2011; 53: 969–976.
24.
BacheletT., CouziL., PitardV.Cytomegalovirus-responsive gammadelta T cells: novel effector cells in antibody-mediated kidney allograft microcirculation lesions.J Am Soc Nephrol2014; 25: 2471–2482.
25.
ShabirS., SmithH., KaulB.Cytomegalovirus-associated CD4(+) CD28(null) cells in NKG2D-dependent glomerular endothelial injury and kidney allograft dysfunction.Am J Transplant2016; 16: 1113–1128.
26.
HeutinckK.M., YongS.L., TonneijckL.Virus-specific CD8(+) T cells cross-reactive to donor-alloantigen are transiently present in the circulation of kidney transplant recipients infected with CMV and/or EBV.Am J Transplant2016; 16: 1480–1491.
27.
NickelP., BoldG., PresberF.High levels of CMV-IE-1-specific memory T cells are associated with less alloimmunity and improved renal allograft function.Transpl Immunol2009; 20: 238–242.
28.
Martín-GandulC., Perez-RomeroP., SanchezM.Determination, validation and standardization of a CMV DNA cut-off value in plasma for preemptive treatment of CMV infection in solid organ transplant recipients at lower risk for CMV infection.J Clin Virol2013; 56: 13–18.
29.
AtabaniS.F., SmithC., AtkinsonC.Cytomegalovirus replication kinetics in solid organ transplant recipients managed by preemptive therapy.Am J Transplant2012; 12: 2457–2464.
30.
LisboaL.F., PreiksaitisJ.K., HumarA., KumarD.Clinical utility of molecular surveillance for cytomegalovirus after antiviral prophylaxis in high-risk solid organ transplant recipients.Transplantation2011; 92: 1063–1068.
31.
LisboaL.F., AsbergA., KumarD.The clinical utility of whole blood versus plasma cytomegalovirus viral load assays for monitoring therapeutic response.Transplantation2011; 91: 231–236.
SawinskiD., FordeK.A., Trofe-ClarkJ.Persistent BK viremia does not increase intermediate-term graft loss but is associated with de novo donor-specific antibodies.J Am Soc Nephrol2015; 26: 966–975.
34.
SchachtnerT., SteinM., BabelN., ReinkeP.The loss of BKV-specific immunity from pretransplantation to posttransplantation identifies kidney transplant recipients at increased risk of BKV replication.Am J Transplant2015; 15: 2159–2169.
35.
ReischigT., PruchaM., SedlackovaL.Valganciclovir prophylaxis against cytomegalovirus impairs lymphocyte proliferation and activation in renal transplant recipients.Antivir Ther2011; 16: 1227–1235.
36.
MartyF.M., WinstonD.J., RowleyS.D.CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation.N Engl J Med2013; 369: 1227–1236.
37.
ChemalyR.F., UllmannA.J., StoelbenS.Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation.N Engl J Med2014; 370: 1781–1789.
38.
HalloranP.F., de FreitasD.G., EineckeG.An integrated view of molecular changes, histopathology and outcomes in kidney transplants.Am J Transplant2010; 10: 2223–2230.
39.
CosioF.G., El TersM., CornellL.D., SchinstockC.A., StegallM.D.Changing kidney allograft histology early posttransplant: prognostic implications of 1-year protocol biopsies.Am J Transplant2016; 16: 194–203.
